These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Immunoactivity of pidotimod against episodes of recurrent tonsillitis in childhood. Motta G, De Campora E, De Vita C, Esposito S, Galletti C, Incutti V, Mallardi V, Motta S, Pucci V, Salonna F. Arzneimittelforschung; 1994 Dec; 44(12A):1521-4. PubMed ID: 7857356 [Abstract] [Full Text] [Related]
23. General pharmacology of pidotimod and testing for drug interactions. Manzardo S, Falcone A, Pinzetta A, Ieva G, Coppi G. Arzneimittelforschung; 1994 Dec; 44(12A):1441-7. PubMed ID: 7857339 [Abstract] [Full Text] [Related]
27. High-performance liquid chromatography-tandem mass spectrometry for the determination of pidotimod in human plasma and its application to a pharmacokinetic study. Zhang Y, Xiong Z, Qin F, Lu S, Liu W, Li F. J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Aug 15; 877(24):2566-70. PubMed ID: 19604731 [Abstract] [Full Text] [Related]
28. Synthesis and preliminary pharmacological evaluation of pidotimod, its enantiomer, diastereomers and carboxamido derivatives. Magni A, Signorelli G, Bocchiola G. Arzneimittelforschung; 1994 Dec 15; 44(12A):1402-4. PubMed ID: 7857331 [Abstract] [Full Text] [Related]
29. Pharmacokinetics of pidotimod in broiler chickens by UHPLC-MS/MS after oral and intravenous administration. Zhang R, Qiu M, Zhao L, Cui L, Wang C, Zhu J, Hao Z. Biomed Chromatogr; 2018 Mar 15; 32(3):. PubMed ID: 29105801 [Abstract] [Full Text] [Related]
34. Pharmacokinetic variability of nimodipine disposition after single and multiple oral dosing to hypertensive renal failure patients: parametric and nonparametric population analysis. Terziivanov D, Atanasova I, Dimitrova V, Robeva R, Unger S, Mück W. Int J Clin Pharmacol Ther; 1999 Aug 15; 37(8):404-12. PubMed ID: 10475143 [Abstract] [Full Text] [Related]
35. Pharmacokinetics of incadronate, a new bisphosphonate, in healthy volunteers and patients with malignancy-associated hypercalcemia. Usui T, Oiso Y, Tomita A, Ogata E, Uchida T, Ikeda K, Watanabe T, Higuchi S. Int J Clin Pharmacol Ther; 1997 Jun 15; 35(6):239-44. PubMed ID: 9208339 [Abstract] [Full Text] [Related]
37. The in vitro effect of Pidotimod on some immune functions in cancer patients. Di Renzo M, Pasqui AL, Bruni F, Saletti M, Bova G, Chiarion C, Girardello R, Ferrì P, Auteri A. Immunopharmacol Immunotoxicol; 1997 Feb 15; 19(1):37-51. PubMed ID: 9049658 [Abstract] [Full Text] [Related]
38. Advantage of population pharmacokinetic method for evaluating the bioequivalence and accuracy of parameter estimation of pidotimod. Huang J, Li M, Lv Y, Yang J, Xu L, Wang J, Chen J, Wang K, He Y, Zheng Q. Int J Clin Pharmacol Ther; 2016 Sep 15; 54(9):682-92. PubMed ID: 27390049 [Abstract] [Full Text] [Related]